Swedish Orphan Biovitrum AB (BIOVF) Q2 2026 Earnings Call Highlights: Strong Revenue Growth and ...

Swedish Orphan Biovitrum AB (BIOVF) Q2 2026 Earnings Call Highlights: Strong Revenue Growth and ...

Stocks snap two-week win streak as AI-trade bleeds, pushing chips into bear market GuruFocus - - Revenue Growth: 29% at constant exchange rates. - Adjusted EBITDA Margin: 35% for Q2. - Total Net Sales: Just under SEK7.8 billion for the quarter.

- Geographic Revenue Growth: North America 33%, International markets 45%, Europe 23%. - Product Performance: Strong contributions from Doptelet, Altuvoct, and Gamifant. - Hemophilia A Sales Growth: 41% at constant exchange rate.

- Operating Expenses Increase: 24% at constant exchange rates. - SG&A Increase: 15% at constant exchange rates. - R&D Expenses Increase: 47% at constant exchange rates.

- Adjusted EBITA: SEK2.8 billion, margin of 35%. - Operating Cash Flow: SEK1.9 billion for the quarter. - Net Debt: Just above SEK16 billion, net debt-to-EBITDA ratio of 1.3 times.

- Full Year Revenue Growth Outlook: Mid- to high teens percentage at constant exchange rates. - Full Year Adjusted EBITDA Margin Outlook: Mid- to high 30s percentage of revenue. For the complete transcript of the earnings call, please refer to the full earnings call transcript.

Positive Points - Swedish Orphan Biovitrum AB (BIOVF) reported a strong Q2 with a 29% revenue growth at constant exchange rates. - The company increased its full-year outlook based on strong first-half performance, reflecting confidence in continued delivery. - Positive data from the REDUCE-2 trial for pozdeutinurad was announced, demonstrating meaningful urate reduction.

- Altuvoct showed strong growth in haemophilia A prophylaxis, with sales increasing significantly year-over-year. - The company is advancing its pipeline with multiple programs, including the initiation of the EMBRACE-II study for Gamifant in interferon gamma-driven sepsis. - Swedish Orphan Biovitrum AB (BIOVF) received a complete response letter from the FDA for NASP related to manufacturing issues.

- R&D expenses increased by 47% at constant exchange rates, driven by the addition of new development programs. - The launch of Aspaveli in nephrology showed a slight decline in sales compared to Q1, raising concerns about its growth trajectory. - The company faces high competition in the market, particularly from Arrowhead in the area of acute pancreatitis.

- There is uncertainty regarding the timeline for NASP resubmission, as the post-CRL FDA meeting has not yet been scheduled. A: Guido Oelkers, CEO, stated that Sobi is confident in Tryngolza’s strong data on sHTG reduction and AP reduction, which sets a high bar for competitors like Arrowhead. Lydia Abad-Franch, Chief Medical Officer, emphasized the importance of efficacy and safety profiles, expressing confidence in Tryngolza’s potential despite competition.

Q: Can you explain the reasons behind the NASP CRL and the impact on the timeline? A: Lydia Abad-Franch explained that the CRL was related to CMC and manufacturing issues, not clinical efficacy or safety. Sobi plans to meet with the FDA to map out timelines and aims to resubmit within 6 to 12 months, with a clear and actionable path forward.

Q: What is the growth potential for Altuvoct, and can double-digit growth be sustained post-2026? A: Guido Oelkers expressed confidence in Altuvoct’s growth trajectory, highlighting significant opportunities in Europe and international markets. The product is on track to reach the SEK10 billion mark, with sustained growth expected beyond 2026.

Q: How is Sobi approaching the Gamifant sepsis opportunity, particularly in the US? A: Guido Oelkers stated that the decision to focus on Europe was driven by speed, with a fast-track approach in collaboration with EMA. Lydia Abad-Franch added that while initial efforts are in Europe, the ultimate goal is global approval, with ongoing discussions with US experts.

Q: What were the biggest drivers for the top-line guidance raise, and how should we model Tryngolza sales in Europe? A: Guido Oelkers identified Doptelet and Altuvoct as key growth drivers exceeding expectations. For Tryngolza, while detailed guidance wasn’t provided, it’s expected to be a significant product with a large market opportunity, potentially taking longer to reach peak sales compared to Altuvoct.

For the complete transcript of the earnings call, please refer to the full earnings call transcript.